Novavax says protein vaccine works for kids as young as 12
By The Associated Press
Novavax says its COVID-19 vaccine is proving safe and effective for kids as young as 12. The Maryland-based company makes a protein-based vaccine that’s been cleared for use in adults in parts of the world including Britain and Europe, and is under review in the U.S. Â Novavax studied more than 2,000 U.S. kids ages 12 to 17 last summer. The company announced Thursday that the shots were 80% effective at preventing symptomatic COVID-19, and it plans to seek expanded use of the vaccine down to age 12.